Escape of SARS-CoV-2 Variants KP.1.1, LB.1, and KP.3.3 From Approved Monoclonal Antibodies
Background: First-generation anti-SARS-CoV-2 monoclonal antibodies (mAbs) used for prophylaxis or therapeutic purposes in immunocompromised patients have been withdrawn because of the emergence of resistant Omicron variants. In 2024, 2 novel mAbs, VYD222/Pemivibart and AZD3152/Sipavibart, were appro...
Saved in:
Main Authors: | Delphine Planas (Author), Isabelle Staropoli (Author), Cyril Planchais (Author), Emilie Yab (Author), Banujaa Jeyarajah (Author), Yannis Rahou (Author), Matthieu Prot (Author), Florence Guivel-Benhassine (Author), Frederic Lemoine (Author), Vincent Enouf (Author), Etienne Simon-Loriere (Author), Hugo Mouquet (Author), Marie-Anne (Author), Olivier Schwartz (Author) |
---|---|
Format: | Book |
Published: |
Case Western Reserve University,
2024-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Emergence of SARS‐CoV‐2 variants KP.2 and KP.3 sparks concerns: What should we do?
by: Balamurugan Shanmugaraj
Published: (2024) -
Inhibitory Effect of KP-A038 on Osteoclastogenesis and Inflammatory Bone Loss Is Associated With Downregulation of Blimp1
by: Hye Jung Ihn, et al.
Published: (2019) -
PELATIHAN EXTRAKURIKULER PADUAN SUARA MELALUI APLIKASI GOOGLE CLASSROOM DI SMA KP 3 PASEH
by: Novianti Ainurokhim, -
Published: (2021) -
Klotho-derived peptide KP1 ameliorates SARS-CoV-2-associated acute kidney injury
by: Jie Xu, et al.
Published: (2024) -
KP LAPE -muutosohjelma, Keski-Pohjanmaan sosiaali- ja terveyspalvelukuntayhtymä Soite
by: Suvi Pokela, et al.
Published: (2018)